MED7 and breast cancer: With respect to other tumors, MED7 underexpression was correlated with an increased risk of gastrointestinal stroma (Koschubs et al., 2009), while in breast cancer, especially ER + luminal subtypes, MED7 was positively correlated with improved prognosis (Joseph et al., 2018).